Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Daiichi Sankyo Co., Ltd. (OTC: DSNKY).

Full DD Report for DSNKY

You must become a subscriber to view this report.


Recent News from (OTC: DSNKY)

Daiichi's quizartinib successful in late-stage AML study
Results from a Phase 3 clinical trial, QuANTUM-R, assessing Daiichi Sankyo's ( OTCPK:DSKYF )( OTCPK:DSNKY ) quizartinib patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3-ITD mutations after first-line treatment with or without hematopoietic stem cell transplantation...
Source: SeekingAlpha
Date: May, 08 2018 10:05
Thermo Fisher inks deals with Daiichi Sankyo and Takeda to expand use of Oncomine Dx in clinical trials
Thermo Fisher Scientific ( TMO -0.4% ) has entered into agreements with Daiichi Sankyo ( OTCPK:DSKYF )( OTCPK:DSNKY ) and Takeda Pharmaceutical Co. ( OTCPK:TKPYY ) aimed at expanding the utility of Fisher's Oncomine Dx Target Test to support each firm's clinical trials and development pr...
Source: SeekingAlpha
Date: May, 01 2018 10:32
Daiichi Sankyo Co., Ltd. ADR 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Daiichi Sankyo Co., Ltd. ADR in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: April, 27 2018 14:23
Daiichi teams up with DarwinHealth to identify new cancer targets
Daiichi Sankyo ( OTCPK:DSKYF )( OTCPK:DSNKY ) inks an agreement with privately held DarwinHealth for exclusive access to the latter's proprietary novel cancer target database aimed at identifying potential new cancer treatments. More news on: Daiichi Sankyo Co., Ltd., Daiichi Sankyo ...
Source: SeekingAlpha
Date: April, 04 2018 09:35
Daiichi to cut 280 U.S. jobs in restructuring
Aimed at streamlining its U.S. operations, Daiichi Sankyo ( OTCPK:DSKYF )( OTCPK:DSNKY ) will cut 280 jobs . More news on: Daiichi Sankyo Co., Ltd., Daiichi Sankyo Co., Ltd. ADR, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: February, 28 2018 15:16
Early-stage study underway assessing Daiichi's ADC candidate DS-1062 in lung cancer
Daiichi Sankyo ( OTCPK:DSKYF )( OTCPK:DSNKY ) announces that dosing is underway in a Phase 1 clinical trial evaluating TROP2-targeting antibody-drug conjugate (ADC) candidate DS-1062 in patients with unresectable advanced non-small cell lung cancer (NSCLC) who have not responded to stand...
Source: SeekingAlpha
Date: February, 22 2018 11:38
Daiichi Sankyo Co., Ltd. ADR 2018 Q3 - Results - Earnings Call Slides
The following slide deck was published by Daiichi Sankyo Co., Ltd. ADR in conjunction with their 2018 Q3 earnings Read more ...
Source: SeekingAlpha
Date: January, 31 2018 14:23
Daiichi Sankyo's lead ADC DS-8201 shows positive effect in early-stage study
Updated data from a Phase 1 clinical trial assessing Daiichi Sankyo's ( OTCPK:DSKYF )( OTCPK:DSNKY ) lead antibody-drug conjugate (ADC) DS-8201 in patients with HER2-positive gastric cancer showed a treatment effect. The results were presented at the ASCO-GI Symposium in San Francisco. ...
Source: SeekingAlpha
Date: January, 18 2018 09:09
Daiichi Sankyo (DSNKY) Investor Presentation - Slideshow
The following slide deck was published by Daiichi Sankyo Co., Ltd. ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: December, 14 2017 14:18
Daiichi Sankyo and Puma Biotech team up with Sloan Kettering to investigate combo therapy for HER-positive tumors
Daiichi Sankyo ( OTCPK:DSKYF )( OTCPK:DSNKY ) and Puma Biotechnology (NYSE: PBYI ) will collaborate with Memorial Sloan Kettering Cancer Center to evaluate the combination of Daiichi's antibody-drug conjugate DS-8201 and Puma's NERLYNX (neratinib) for the treatment of HER2-positive solid t...
Source: SeekingAlpha
Date: December, 12 2017 16:38

 


About Daiichi Sankyo Co., Ltd. (OTC: DSNKY)

Logo for Daiichi Sankyo Co., Ltd. (OTC: DSNKY)

Founded on September , through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo delivers innovative products that enhance the lives of millions of people around the world. Our recent successes include the antihypertensive agent olmesartan Olmetec , launched in by Sankyo and now available in more than countries around the world the antiplatelet agent prasugrel Efient , launched in for patients with acute coronary syndrome ACS undergoing percutaneous coronary intervention PCI and edoxaban Lixiana , the first available factor Xa inhibitor in Japan, which launched in to help prevent venous thromboembolism VTE .

 

Contact Information

 

 

Current Management

  • Takashi Shoda / CEO

Current Share Structure

  • Market Cap: $25,049,369,229 - 03/09/2018
  • Issue and Outstanding: 709,011,300 - 10/31/2011

 



Daily Technical Chart for (OTC: DSNKY)

Daily Technical Chart for (OTC: DSNKY)


Stay tuned for daily updates and more on (OTC: DSNKY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: DSNKY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DSNKY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of DSNKY and does not buy, sell, or trade any shares of DSNKY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/